PG
MYGN icon

PEAK6 Group’s Myriad Genetics MYGN Stock Holding History

PEAK6 Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,392
Closed -$283K – 4734
2018
Q1 		$248K Sell
8,392
-745
-8% -$25.2K ﹤0.01% 3201
2017
Q4 		$314K Buy
+9,137
New +$308K ﹤0.01% 2831
2014
Q4 		– Sell
-74
Closed -$2.63K – 4966
2014
Q3 		$3K Sell
74
-2,230
-97% -$83.2K ﹤0.01% 4559
2014
Q2 		$90K Buy
+2,304
New +$85.7K ﹤0.01% 3785
2013
Q3 		– Sell
-8,700
Closed -$234 – 5339
2013
Q2 		$234 Buy
+8,700
New +$252K ﹤0.01% 3482

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PEAK6 Group's MYGN Position: Q2 2018 in Review

PEAK6 Group sold out of Myriad Genetics (MYGN) in Q2 2018, closing a stake of 8,392 shares — an estimated $283K sold.

PEAK6 Group first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $314K in Q4 2017. 258 funds tracked by Wall St. Rank hold MYGN as of Q2 2018.

  • PEAK6 Group reported no remaining Myriad Genetics position as of Q2 2018 after selling out during the quarter.
  • PEAK6 Group sold 8,392 Myriad Genetics shares in Q2 2018, an estimated $283K.
  • PEAK6 Group first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
  • PEAK6 Group's Myriad Genetics position peaked at $314K in Q4 2017.
  • 258 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.